Scientists Identify Gene Vital to Early Embryonic Cells Forming a Normal Heart and Skull
In a study posted online June 15, 2009 by the Proceedings of the National Academy of Sciences, a research team at Cincinnati Childrens reports that too little of the gene/protein SHP2 interferes with the normal developmental activity of what are called neural crest cells. These cells, which occur very early in embryonic development, migrate to specific regions of the embryo. While doing so, the cells are supposed to differentiate and give rise to certain nerve tissues, craniofacial bones or smooth muscle tissue of the heart.
Our findings show that a deficiency of SHP2 in neural crest cells results in a failure of cell differentiation at diverse sites in the developing embryo, said Jeffrey Robbins, PhD, co-director of the Heart Institute at Cincinnati Childrens and senior investigator of the study. This leads to anatomical and functional deficits so severe that it precludes viability of the developing fetus.
SHP2 is a tyrosine phosphatase an enzyme that helps trigger a cascade of biochemical reactions in cells as they specify to form certain tissues.
Although the study was conducted using mouse embryos, the findings are significant in efforts to understand congenital malformations of the heart and craniofacial region in people. Especially relevant, the researchers said, is the insight gained into early molecular events during embryonic development that might help explain such birth defects.
Robbins, professor of pediatrics at the
The study was supported by grants from the National Institutes of Health. Other researchers include first author, Tomoki Nakamura, along with James Gulick, and Melissa Colbert, all of the division of molecular cardiovascular biology at Cincinnati Childrens.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.